Page last updated: 2024-09-03

imatinib mesylate and Bednar Tumor

imatinib mesylate has been researched along with Bednar Tumor in 100 studies

Research

Studies (100)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.00)	18.2507
2000's	42 (42.00)	29.6817
2010's	45 (45.00)	24.3611
2020's	12 (12.00)	2.80

Authors

Authors	Studies
Gounder, MM; Mori, S; Navarrete-Dechent, C; Nehal, KS; Shah, K; Stambuk, HE	1
Barrios Barreto, R; De La Hoz Pabola, A; Del Valle, A; Mendoza Suarez, L; Silvera Redondo, C	1
Amagai, R; Asano, Y; Fujimura, T; Hashimoto, A; Kambayashi, Y; Kasahara, Y; Ohuchi, K	1
Berman, RS; Lee, AY; Vitiello, GA	1
Adams, A; Batchu, S; Cerniglia, KS; Goodwin, BJ; Henry, OS; Hong, YK; Platoff, R; Sandilos, G	1
Buljan, M; Crnarić, I; Delaš Aždajić, M; Šitum, M; Vučić, M	1
Alacacıoğlu, A; Bütün, O; Demirdöver, C; Güç, H; Güç, ZG	1
Levell, NJ; Lim, SX; Ramaiya, A; Venables, ZC	1
Ahn, C; Allen, A; Sangüeza, OP	1
Brown, R; Caliskan, PM; Cove, L; David, MP; Dicker, G; Funderburg, A; Gardner, JM; Hoffman, L; Horne, T; Selig, JP	1
Boukhar, SA; McGee, MW; Monga, V; Phadke, SD; Weigel, R	1
Bielack, SS; Feuchtgruber, S; Fuchs, J; Hettmer, S; Klingebiel, T; Koscielniak, E; Krewer, J; Mentzel, T; Münter, M; Niggli, F; Rolle, U; Scheer, M; Seitz, G; Sparber-Sauer, M; Vokuhl, C; von Kalle, T	1
Charvát, M; Grossmann, P; Hrudka, J; Kinkor, Z	1
Biatta, CM; Centurioni, MG; Comandini, D; Cozzani, E; Franchelli, S; Merlo, G; Parodi, A; Trave, I; Vellone, VG; Zena, M	1
Shah, A; Sharma, S; Tassavor, M; Torbeck, R	1
Dębiec-Rychter, M; Jagielska, B; Klimczak, A; Pieńkowska-Grela, B; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I	1
Bambara, HA; Lamien/Sanou, A; Ouédraogo Nde, NA; Ouédraogo, MS; Ouédraogo, NA; Tapsoba, GP; Thouraya Chtioui, A; Tiemtoré-Kambou, BM; Traoré, F; Zongo, N	1
Adabra, K; Amavi, AK; Dosseh, ED; Dossouvi, T; Padaro, E	1
Aggarwal, A; Barwad, A; Dhamija, E; Panday, R; Rastogi, S; Sharma, A	1
Ben-Ami, E; Castells, MC; Connell, NT; Rutherford, AE; Thornton, KA	1
Alsina, M; Llombart, B; Morgado-Carrasco, D; Requena, C; Sanmartín, O; Serra, C; Través, V	1
Barker, CA; Dickson, MA; Mori, S; Navarrete-Dechent, C; Nehal, KS	1
Amadour, L; Arifi, S; Benbrahim, Z; Elmernissi, F; Elmrabet, F; Harmouch, T; Mellas, N; Ouahbi, H; Oufkigh, AA; Tahiri, L	1
Haas, RL; Kerst, JM; Klomp, HM; van Boven, HH; van Coevorden, F; van der Hage, JA; van Huizum, MA; Wicherts, DA	1
Colegio, OR; Liu, LS	1
Akram, J; Lock-Andersen, J; Wooler, G	1
Choi, DI; Hong, JY; Kang, SW; La Choi, Y; Lee, J; Li, M; Liu, X; Mao, M	1
Becker, JC; Hauschild, A; Hein, R; Helmbold, P; Kämpgen, E; Kellner, I; Leverkus, M; Mentzel, T; Mohr, P; Pföhler, C; Schadendorf, D; Schiller, M; Ströbel, P; Ugurel, S; Utikal, J	1
Kallini, JR; Khachemoune, A	1
Blay, JY; Cassier, P; Dufresne, A; Heudel, P; Pissaloux, D; Ray-Coquard, I; Wang, Q	1
Bahri, N; Czaplinski, JT; Eilers, G; Fletcher, JA; Hornick, JL; Lindeman, NI; Mariño-Enriquez, A; Mayeda, M; Sicinska, E; Tao, D; Wagner, AJ; Zhu, M	1
Amin, A; Aslam, HM; Bashir, S; Hashmi, AS; Malik, B; Mumtaz, S; Tariq, M	1
Chen, J; Chen, Y; Luo, Z; Shi, Y; Wang, C; Zhang, R; Zheng, B	1
Astolfi, A; Casali, PG; Castelli, C; Conca, E; Dagrada, GP; Dei Tos, AP; Fiore, M; Gronchi, A; Grosso, F; Indio, V; Maestro, R; Negri, T; Palassini, E; Pantaleo, MA; Pilotti, S; Stacchiotti, S; Tazzari, M; Urbini, M; Vincenzi, B	1
Bhayani, MK; Montague, GL; Pease, G	1
Fukushima, T; Gomi, D; Kobayashi, T; Koizumi, T; Sakamoto, A; Sano, K; Sasaki, S; Sekiguchi, N; Tatai, T	1
Arienti, F; Astolfi, A; Camisaschi, C; Casali, PG; Castelli, C; Dagrada, GP; De Cecco, L; Fiore, M; Gronchi, A; Indio, V; Lombardo, C; Negri, T; Pantaleo, MA; Pilotti, S; Rini, F; Rivoltini, L; Stacchiotti, S; Tazzari, M; Vergani, B; Villa, A	1
Becker, JC; Ugurel, S	1
Linden, KG; Ortiz, AE; Wu, JJ	1
Goldenberg, G; Golitz, LE; McCarter, M; McClain, D; Thomison, J	1
Aklan, T; Hoeffken, K; Lemm, D; Mentzel, T; Muegge, LO; Schultze-Mosgau, S; Thorwarth, M	1
Chudenko, VA; Gafton, GI; Imianitov, EN; Kochnev, VA; Matsko, DE; Mikhaĭlichenko, TD; Moiseenko, VM; Nogaeva, TKh; Orlova, RV; Protsenko, SA	1
Höffken, K; Lemm, D; Mentzel, T; Mügge, LO	1
Duffaud, F; Le Cesne, A	1
Chen, EH; Han, A; Niedt, G; Ratner, D; Sherman, W	1
Almenar, S; Guillén, C; Llombart, B; Llombart-Bosch, A; López-Guerrero, JA; Monteagudo, C; Poveda, A; Requena, C; Sanmartín, O; Serra, C; Vistós, JL	1
Adamson, DC; Cummings, TJ; Grossi, PM; Mattox, AK; Mehta, AI	1
Bernengo, MG; Fava, P; Savoia, P; Stroppiana, E	1
Bartal, A; Bocs, K; Hitre, E; Langmár, Z; Liszkay, G; Mátrai, Z; Orosz, Z; Plotár, V; Rényi Vámos, F; Sávolt, A; Székely, J; Tóth, L	1
Baker, LH; Verweij, J	1
Debiec-Rychter, M; Gelderblom, H; Hohenberger, P; Lazar, A; Lopez-Terrada, D; Rankin, CJ; Rubin, BP; Ruka, W; Rutkowski, P; Schuetze, SM; Sciot, R; Van Glabbeke, M; van Oosterom, AT	1
Aubin, F; Bodokh, I; Boulinguez, S; Calvo, F; D'Incan, M; Dalle, S; de Kerviler, E; Janin, A; Kérob, D; Lebbe, C; Madelaine-Chambrin, I; Mathieu-Boue, A; Maubec, E; Pedeutour, F; Porcher, R; Servant, JM; Vérola, O	1
Dębiec-Rychter, M; Michej, W; Nowecki, Z; Ptaszynski, K; Ruka, W; Rutkowski, P; Symonides, M	1
de Waard-van der Spek, FB; den Hollander, JC; Gooskens, SL; Oranje, AP; van Adrichem, LN; van de Ven, CP; van den Heuvel-Eibrink, MM	1
Johnson-Jahangir, H; Ratner, D; Sherman, W	1
Casali, PG; Collini, P; Conca, E; Gronchi, A; Keslair, F; Marrari, A; Morosi, C; Negri, T; Palassini, E; Pedeutour, F; Pilotti, S; Stacchiotti, S	1
Martin, L	1
O'Bryan, KW; Ratner, D	1
Li, QW; Lu, JY; Sun, JZ; Wang, RL; Xiao, WH; Zhu, JH	1
Kobayashi, K; Kobayashi, R; Mikawa, M; Morioka, K; Suzuki, D; Yamamoto, H; Yasuda, K	1
Balagula, Y; Maki, RG; Myskowski, PL; Pulitzer, MP	1
Malhotra, B; Schuetze, SM	1
Cao, X; Chen, Y; Luo, Z; Shi, Y; Wang, C; Wang, J; Zhang, R; Zheng, B	1
Clarke, LE	1
Jeon, IK; Kim, JH; Kim, SC; Kim, SE; Roh, MR	1
Llombart, B; López Guerrero, JA; Monteagudo, C; Sanmartín, O; Serra-Guillén, C	1
Blay, JY; Ray-Coquard, I	1
Sawyers, CL	1
Bruckner, JD; Conrad, EU; Eary, JF; Mirza, S; Norwood, TH; Rubin, BP; Schuetze, SM	1
Antonescu, CR; Awan, RA; Dixon, RH; Jhanwar, S; Maki, RG	1
Kuenen, BC; Pinedo, HM	1
Baars, A; Pinedo, HM	1
McArthur, G	2
Hara, K; Matsumoto, Y; Mizutani, K; Saeki, H; Tamada, Y; Tamaki, K; Tsuzuki, T	1
Cole, W; Fletcher, JA; Manson, DE; Pappo, AS; Price, VE; Stuart, M; Viero, S; Zielenska, M	1
Corless, CL; Debiec-Rychter, M; Demetri, GD; Dimitrijevic, S; Fletcher, JA; Heinrich, MC; McArthur, GA; Nikolova, Z; van Oosterom, A	1
Fletcher, JA; Labropoulos, SV; Oliveira, AM; Papadopoulos, S; Razis, ED	1
Jones, RL; Judson, IR	1
Eckhardt, S	1
Scheinfeld, N; Schienfeld, N	1
Bigby, SM; Lambie, NK; Oei, P; Symmans, PJ	1
Devere, TS; Heinrich, MC; Lee, KK; Mehrany, K; Swanson, NA; Weenig, RH; White, CR	1
McArthur, GA	2
Choi, WS; Chung, HS; Kim, SD; Kim, SH; Lim, DJ; Park, JY	1
Bernengo, MG; Ortoncelli, M; Quaglino, P; Savoia, P	1
Awada, A; De Saint Aubain, N; Flamen, P; Gil, T; Kasper, B; Lossignol, D	1
Bianchini, L; Maire, G; Pedeutour, F	1
Ugurel, S	1
Guillén, C; Llombart, B; López-Guerrero, JA; Requena, C; Sanmartín, O; Serra, C	1
Petersen, JE; Wright, TI	1
Nishida, T	1
Fernandez-Flores, A	1
Alberti, L; Arifi, S; Blay, JY; Cassier, P; Decouvelaere, AV; Dufresne, A; El Sayadi, H; Fayette, J; Méeus, P; Ranchère, D; Ray-Coquard, I; Tabone-Eglinger, S	1
Bousquet, G; Calvo, F; de Kerviler, E; Janin, A; Kerob, D; Lebbe, C; Leboeuf, C; Madelaine-Chambrin, I; Pedeutour, F; Pruvost, C; Sarandi, F; Servant, JM; Verola, O	1
Handolias, D; McArthur, GA	1
Buchdunger, E; Collins, VP; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T	1
Cleris, L; Formelli, F; Greco, A; Miranda, C; Pierotti, MA; Roccato, E	1
Buchdunger, E; Dal Cin, P; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T	1

Reviews

29 review(s) available for imatinib mesylate and Bednar Tumor

Article	Year
Dermatofibrosarcoma Protuberans: What Is This? The Surgical clinics of North America, 2022, Volume: 102, Issue:4 Topics: Dermatofibrosarcoma; Humans; Imatinib Mesylate; Margins of Excision; Skin Neoplasms	2022
Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review. American journal of surgery, 2023, Volume: 225, Issue:2 Topics: Adolescent; Adult; Aged; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Skin Neoplasms; Tyrosine Kinase Inhibitors; Young Adult	2023
Dermatofibrosarcoma Protuberans. Dermatologic clinics, 2019, Volume: 37, Issue:4 Topics: Antineoplastic Agents; Dermatofibrosarcoma; Dermatologic Surgical Procedures; Humans; Imatinib Mesylate; Margins of Excision; Mohs Surgery; Oncogene Proteins, Fusion; Skin Neoplasms; Translocation, Genetic	2019
Guidelines for Diagnosis and Treatment of Cutaneous Sarcomas: Dermatofibrosarcoma Protuberans. Actas dermo-sifiliograficas, 2018, Volume: 109, Issue:10 Topics: Antineoplastic Agents; Combined Modality Therapy; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Grading; Neoplasm Staging; Oncogene Proteins, Fusion; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sarcoma; Skin Neoplasms	2018
Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review. JAMA dermatology, 2019, 03-01, Volume: 155, Issue:3 Topics: Adult; Aged; Dermatofibrosarcoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Skin Neoplasms; Survival Analysis; Treatment Outcome; Young Adult	2019
[Outcome of locally advanced Darier and Ferrand dermatofibrosarcoma: about a case and literature review]. The Pan African medical journal, 2019, Volume: 32 Topics: Antineoplastic Agents; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Skin Neoplasms; Treatment Outcome; Young Adult	2019
Molecularly targeted therapies for nonmelanoma skin cancers. International journal of dermatology, 2013, Volume: 52, Issue:6 Topics: Anilides; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyridines; Pyrimidines; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms	2013
Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:12 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Young Adult	2014
[Molecular biology of sarcoma and therapeutic choices]. Bulletin du cancer, 2015, Volume: 102, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzamides; Bone Neoplasms; Crizotinib; Denosumab; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Deletion; Giant Cell Tumor of Bone; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Piperazines; Point Mutation; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sarcoma; Sarcoma, Ewing; Sunitinib; Synovitis, Pigmented Villonodular; Translocation, Genetic	2015
Current treatment options in dermatofibrosarcoma protuberans. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cell Division; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Microsurgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Skin Neoplasms	2009
Imatinib in the treatment of solid tumours. Targeted oncology, 2009, Volume: 4, Issue:1 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Clinical Trials as Topic; Dermatofibrosarcoma; Fibromatosis, Aggressive; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms; Treatment Outcome	2009
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cytotoxins; Dermatofibrosarcoma; Disease Progression; Gastrointestinal Stromal Tumors; Hemangioendothelioma; Hemangiosarcoma; Humans; Imatinib Mesylate; Leiomyosarcoma; Liposarcoma, Myxoid; Piperazines; Pyrimidines; Research Design; Sarcoma; Sarcoma, Synovial; Skin Neoplasms	2010
Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatric blood & cancer, 2010, Volume: 55, Issue:2 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child, Preschool; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Infant; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome	2010
[What's new in dermatological treatments?]. Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4 Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab	2010
The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:1 Topics: Anilides; Antineoplastic Agents; Benzamides; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatofibrosarcoma; ErbB Receptors; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms, Squamous Cell; Piperazines; Pyridines; Pyrimidines; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck	2011
Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Current opinion in oncology, 2012, Volume: 24, Issue:4 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2012
Fibrous and fibrohistiocytic neoplasms: an update. Dermatologic clinics, 2012, Volume: 30, Issue:4 Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; beta Catenin; Dermatofibrosarcoma; Fibromatosis, Abdominal; Histiocytoma, Malignant Fibrous; Humans; Imatinib Mesylate; Myxosarcoma; Neprilysin; Neurothekeoma; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Skin Neoplasms; Solitary Fibrous Tumors	2012
Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Seminars in diagnostic pathology, 2013, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Skin Neoplasms; Translocation, Genetic	2013
Molecularly targeted treatment for dermatofibrosarcoma protuberans. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Drug Delivery Systems; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2004
Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Lumbosacral Region; Lung Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed	2004
The development and application of imatinib. Expert opinion on drug safety, 2005, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines	2005
[Clinical studies with imatinib in 2004]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2005
A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:2 Topics: Animals; Benzamides; Dermatofibrosarcoma; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Skin Neoplasms	2006
Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Current opinion in oncology, 2006, Volume: 18, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Middle Aged; Models, Genetic; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin Neoplasms; Treatment Outcome	2006
[Dermatofibrosarcoma protuberans]. Actas dermo-sifiliograficas, 2007, Volume: 98, Issue:2 Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Combined Modality Therapy; Dermatofibrosarcoma; Drug Design; Humans; Imatinib Mesylate; Mohs Surgery; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Ring Chromosomes; Sarcoma; Skin Neoplasms; Translocation, Genetic	2007
Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. Journal of the National Comprehensive Cancer Network : JNCCN, 2007, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dermatofibrosarcoma; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Humans; Imatinib Mesylate; Molecular Biology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiotherapy, Adjuvant; Skin Neoplasms	2007
Dermatofibrosarcoma protuberans: recent clinical progress. Annals of surgical oncology, 2007, Volume: 14, Issue:10 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Clinical Trials as Topic; Combined Modality Therapy; Dermatofibrosarcoma; Dermatologic Surgical Procedures; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin; Skin Neoplasms; Translocation, Genetic	2007
[Imatinib and solid tumours]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasms; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2008
Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. Future oncology (London, England), 2008, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Autocrine Communication; Benzamides; Dermatofibrosarcoma; Epidermal Growth Factor; ErbB Receptors; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Intercellular Signaling Peptides and Proteins; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptor, IGF Type 1; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2008

Trials

3 trial(s) available for imatinib mesylate and Bednar Tumor

Article	Year
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jan-15, Volume: 20, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers; Dermatofibrosarcoma; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2014
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-15, Volume: 16, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Skin Neoplasms; Treatment Outcome	2010
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dermatofibrosarcoma; Disease-Free Survival; Female; Gene Rearrangement; Genes, sis; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2005

Other Studies

68 other study(ies) available for imatinib mesylate and Bednar Tumor

Article	Year
Facial subcutaneous dermatofibrosarcoma protuberans treated with imatinib and monitored with magnetic resonance: A therapeutic alternative for unresectable cases. Dermatologic therapy, 2022, Volume: 35, Issue:6 Topics: Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Skin Neoplasms	2022
Dermatofibrosarcoma protuberans with unusual presentation in vulva. Medicina, 2022, Volume: 82, Issue:3 Topics: Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Skin Neoplasms; Translocation, Genetic; Vulva	2022
Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate. Dermatologic therapy, 2022, Volume: 35, Issue:10 Topics: B7-H1 Antigen; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Ki-67 Antigen; Skin Neoplasms	2022
From Morphea to Dermatofibrosarcoma Protuberans. Acta dermatovenerologica Croatica : ADC, 2022, Volume: 30, Issue:2 Topics: Adult; Cicatrix; Dermatofibrosarcoma; Disease Progression; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Scleroderma, Localized; Skin Neoplasms; Young Adult	2022
Oncological efficiency of wide local excision in dermatofibrosarcoma protuberans. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 77 Topics: Dermatofibrosarcoma; Follow-Up Studies; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms	2023
Review of dermatofibrosarcoma protuberans. Clinical and experimental dermatology, 2023, Mar-22, Volume: 48, Issue:4 Topics: Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-sis; Skin Neoplasms	2023
Perspectives of Patients With Dermatofibrosarcoma Protuberans on Diagnostic Delays, Surgical Outcomes, and Nonprotuberance. JAMA network open, 2019, 08-02, Volume: 2, Issue:8 Topics: Adult; Delayed Diagnosis; Dermatofibrosarcoma; Diagnostic Errors; Female; Humans; Imatinib Mesylate; Interdisciplinary Placement; Male; Middle Aged; Mohs Surgery; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Radiotherapy; Risk Assessment; Self-Help Groups; Skin Neoplasms; Social Media; Surveys and Questionnaires; Treatment Outcome	2019
Dermatofibrosarcoma protuberans - the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report. Journal of medical case reports, 2019, Dec-19, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Skin Neoplasms; Treatment Outcome	2019
Dermatofibrosarcoma protuberans in children and adolescents: Primary and Relapsed disease-Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS). Journal of surgical oncology, 2020, Volume: 122, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Child; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Oncogene Proteins, Fusion; Prognosis; Progression-Free Survival; Registries; Retrospective Studies; Skin Neoplasms; Young Adult	2020
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: a case report. Ceskoslovenska patologie, 2020,Spring, Volume: 56, Issue:2 Topics: Dermatofibrosarcoma; Fibrosarcoma; Humans; Imatinib Mesylate; Male; Skin Neoplasms; Translocation, Genetic	2020
Neoadjuvant imatinib as treatment preceding surgery for vulvar dermatofibrosarcoma protuberans. Dermatologic therapy, 2021, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Preoperative Care; Skin Neoplasms	2021
The various treatment modalities of dermatofibrosarcoma protuberans. Dermatology online journal, 2021, Jun-15, Volume: 27, Issue:6 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Skin Neoplasms	2021
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease-Free Survival; Extremities; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Soft Tissue Neoplasms; Torso; Treatment Outcome; Young Adult	2017
Breast and pleuropulmonary metastasis of multirecurrent scalp dermatofibrosarcoma protuberans: a case report. Journal of medical case reports, 2017, Apr-08, Volume: 11, Issue:1 Topics: Adult; Alopecia; Antigens, CD34; Antineoplastic Agents; Biopsy; Breast Neoplasms; Cough; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Recurrence, Local; Pleural Neoplasms; Prognosis; Scalp; Skin Neoplasms; Treatment Outcome	2017
[Management for locally advanced dermatofibrosarcoma protuberans in Togo]. Bulletin du cancer, 2018, Volume: 105, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Skin Neoplasms; Togo; Young Adult	2018
Advanced Dermatofibrosarcoma Protuberans Treatment With Imatinib: Experience From a Dedicated Sarcoma Medical Oncology Clinic in India. Journal of global oncology, 2018, Volume: 4 Topics: Adult; Dermatofibrosarcoma; Humans; Imatinib Mesylate; India; Medical Oncology; Middle Aged; Sarcoma; Young Adult	2018
Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management. Anti-cancer drugs, 2018, Volume: 29, Issue:9 Topics: Adult; Antineoplastic Agents; Dermatofibrosarcoma; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Hypersensitivity Syndrome; Humans; Imatinib Mesylate; Male; Prednisone; Skin Neoplasms	2018
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World journal of surgical oncology, 2013, Mar-08, Volume: 11 Topics: Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Treatment Outcome	2013
Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines. Journal of plastic surgery and hand surgery, 2014, Volume: 48, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Denmark; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Piperazines; Plastic Surgery Procedures; Practice Guidelines as Topic; Prognosis; Pyrimidines; Retrospective Studies; Skin Neoplasms; Skin Transplantation; Young Adult	2014
Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing. PloS one, 2013, Volume: 8, Issue:7 Topics: Benzamides; CARD Signaling Adaptor Proteins; Carrier Proteins; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Female; GTPase-Activating Proteins; Humans; Imatinib Mesylate; In Vitro Techniques; Matrix Attachment Region Binding Proteins; Middle Aged; Nuclear Matrix-Associated Proteins; Piperazines; Pyrimidines; Receptors, Estrogen	2013
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Molecular cancer therapeutics, 2015, Volume: 14, Issue:6 Topics: Adult; Aged; Aminopyridines; Animals; Blotting, Western; Cell Line, Tumor; Collagen Type I; Collagen Type I, alpha 1 Chain; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p16; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Gene Deletion; Gene Fusion; Humans; Imatinib Mesylate; Mice; Middle Aged; Phosphorylation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-sis; Purines; Pyridines; Retinoblastoma Protein; RNA Interference; Xenograft Model Antitumor Assays; Young Adult	2015
Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case report. Journal of medical case reports, 2015, Apr-29, Volume: 9 Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Combined Modality Therapy; Dermatofibrosarcoma; Eye Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Male; Middle Aged; Oncogene Proteins, Fusion; Orbit; Skin Neoplasms	2015
Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Medicine, 2015, Volume: 94, Issue:17 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; China; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2015
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Feb-15, Volume: 22, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2016
New Facial Weakness After 5 Years of Facial Asymmetry. JAMA otolaryngology-- head & neck surgery, 2016, 11-01, Volume: 142, Issue:11 Topics: Adult; Antineoplastic Agents; Dermatofibrosarcoma; Facial Asymmetry; Facial Paralysis; Humans; Imatinib Mesylate; Male; Parotid Neoplasms; Time Factors	2016
Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:17 Topics: Abdomen; Antineoplastic Agents; Dermatofibrosarcoma; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Skin Neoplasms	2016
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. The Journal of investigative dermatology, 2017, Volume: 137, Issue:2 Topics: Adaptive Immunity; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Dermatofibrosarcoma; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Lectins, C-Type; Myeloid Cells; Receptors, Cell Surface; Skin Neoplasms; T-Lymphocytes	2017
Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy? The Journal of investigative dermatology, 2017, Volume: 137, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunotherapy; Piperazines; Pyrimidines; Skin Neoplasms	2017
Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2008, Volume: 34, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Skin Neoplasms	2008
Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. Journal of cutaneous pathology, 2008, Volume: 35, Issue:11 Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Collagen; Combined Modality Therapy; Dermatofibrosarcoma; Female; Humans; Hyalin; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms	2008
Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Oral and maxillofacial surgery, 2008, Volume: 12, Issue:4 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Scalp; Skin Neoplasms	2008
[Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans]. Voprosy onkologii, 2008, Volume: 54, Issue:5 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult	2008
Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Archives of dermatology, 2009, Volume: 145, Issue:7 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Skin Neoplasms	2009
Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Histopathology, 2009, Volume: 54, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Collagen Type I; Collagen Type I, alpha 1 Chain; Dermatofibrosarcoma; DNA Primers; Female; Gene Fusion; Genes, sis; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Piperazines; Pyrimidines; Skin Neoplasms; Young Adult	2009
Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. Journal of neurosurgery, 2010, Volume: 112, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Collagen Type I; Collagen Type I, alpha 1 Chain; Dermatofibrosarcoma; Epidermal Growth Factor; Humans; Imatinib Mesylate; Male; Middle Aged; Neurosurgical Procedures; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Scalp; Skin Neoplasms; Treatment Outcome	2010
Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Nevus, Halo; Piperazines; Pyrimidines; Skin Neoplasms	2010
[Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans]. Orvosi hetilap, 2009, Oct-11, Volume: 150, Issue:41 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Skin Neoplasms	2009
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-01, Volume: 28, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dermatofibrosarcoma; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines	2010
Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. Journal of the European Academy of Dermatology and Venereology : JEADV, 2011, Volume: 25, Issue:3 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Collagen Type I; Collagen Type I, alpha 1 Chain; Combined Modality Therapy; Dermatofibrosarcoma; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Retrospective Studies; Sarcoma; Skin Neoplasms; Treatment Outcome	2011
Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms	2010
Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. International journal of cancer, 2011, Oct-01, Volume: 129, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies	2011
[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Edema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Skin Neoplasms; Survival Rate; Vomiting	2011
Congenital dermatofibrosarcoma protuberans in a newborn infant with a massive back tumor: favorable effects of oral imatinib on the control of residual tumor growth. Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:7 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Infant, Newborn; Neoplasm, Residual; Piperazines; Pyrimidines	2011
Pigmentary changes in a patient treated with imatinib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Follow-Up Studies; Hair Color; Humans; Hyperpigmentation; Imatinib Mesylate; Male; Piperazines; Pyrimidines; Skin Pigmentation	2011
Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible? European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2012, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Remission Induction; Tomography, X-Ray Computed	2012
Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery. The Journal of dermatology, 2013, Volume: 40, Issue:4 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dermatofibrosarcoma; Female; Fingers; Humans; Imatinib Mesylate; Middle Aged; Mohs Surgery; Piperazines; Pyrimidines; Treatment Outcome	2013
[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]. Bulletin du cancer, 2002, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Florida; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Skin Neoplasms	2002
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2002
Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Radionuclide Imaging; Skin Neoplasms; Spinal Cord Neoplasms	2002
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. International journal of cancer, 2002, Aug-20, Volume: 100, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Recurrence; Sarcoma; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2002
[New oncological treatment principle with imatinib]. Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stromal Cells; Treatment Outcome	2003
[Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans]. Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42 Topics: Adult; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms; Treatment Outcome	2003
Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatric blood & cancer, 2005, Volume: 44, Issue:5 Topics: Benzamides; Dermatofibrosarcoma; Female; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Leg; Magnetic Resonance Imaging; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Tumor Burden	2005
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anti-cancer drugs, 2005, Volume: 16, Issue:4 Topics: Benzamides; Chromosome Aberrations; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Skin Neoplasms	2005
Dermatofibrosarcoma protuberans: report of a case with a variant ring chromosome and metastases following pregnancy. Journal of cutaneous pathology, 2006, Volume: 33, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Breast Neoplasms; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization; Lung Neoplasms; Mastectomy; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Ring Chromosomes; Skin Neoplasms	2006
Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2006, Volume: 32, Issue:3 Topics: Antineoplastic Agents; Benzamides; Cheek; Dermatofibrosarcoma; Facial Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms	2006
Intracranial recurrence of the scalp dermatofibrosarcoma. Clinical neurology and neurosurgery, 2007, Volume: 109, Issue:2 Topics: Adult; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Sinuses; Dermatofibrosarcoma; Embolization, Therapeutic; Female; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Scalp; Skin Neoplasms; Skull Neoplasms	2007
Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2006, Volume: 32, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Diagnostic Imaging; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms; Thorax	2006
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anti-cancer drugs, 2006, Volume: 17, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Scalp; Skin Neoplasms; Tomography, X-Ray Computed	2006
[From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors]. Bulletin du cancer, 2007, Volume: 94, Issue:2 Topics: Adult; Age Factors; Antineoplastic Agents; Benzamides; Child; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Ring Chromosomes; Skin Neoplasms; Translocation, Genetic	2007
[Targeted therapy of dermatofibrosarcoma with imatinib]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials, Phase II as Topic; Dermatofibrosarcoma; Disease-Free Survival; Drug Delivery Systems; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2007
Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2007, Volume: 33, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Scalp; Skin Neoplasms	2007
[Imatinib . Sunitinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate	2007
Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2007, Volume: 48, Issue:4 Topics: Antineoplastic Agents; Benzamides; Biopsy; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2007
Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-01, Volume: 26, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Piperazines; Positron-Emission Tomography; Pyrimidines; Skin Neoplasms	2008
The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer research, 1999, Aug-01, Volume: 59, Issue:15 Topics: 3T3 Cells; Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Transformation, Neoplastic; Cosmids; Dermatofibrosarcoma; Enzyme Inhibitors; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Oncogene Proteins, Fusion; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	1999
Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. International journal of cancer, 2001, May-01, Volume: 92, Issue:3 Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease Models, Animal; Gene Rearrangement; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta	2001
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer research, 2001, Aug-01, Volume: 61, Issue:15 Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Child, Preschool; Dermatofibrosarcoma; Female; Fibrosarcoma; Giant Cell Tumors; Growth Inhibitors; Humans; Imatinib Mesylate; Infant; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Xenograft Model Antitumor Assays	2001